ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · May 13, 2021

Keywords

ClinConnect Summary

This clinical trial is studying two different treatment options for patients with breast cancer who have had chemotherapy and still have cancer in their sentinel lymph nodes (the first lymph nodes to which cancer is likely to spread). The trial aims to find out if using axillary radiotherapy (ART), which uses targeted radiation to treat the lymph nodes, is better at reducing the risk of lymphedema (swelling caused by fluid build-up) compared to a more invasive procedure called axillary lymph node dissection (ALND), where the lymph nodes are surgically removed. The researchers are also looking at how these treatments affect cancer recurrence, overall survival rates, and the quality of life for patients.

To be eligible for this trial, participants should be adults aged 65 to 74 who have been diagnosed with breast cancer and have a specific type of lymph node involvement after receiving neoadjuvant treatment (which is chemotherapy given before surgery). They need to have completed most of their chemotherapy and have not had certain previous cancers or breast surgeries in the last few years. If you choose to participate, you can expect to undergo regular assessments and be part of a study that may help improve treatment options for future breast cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • T1-T4 N0/ T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment
• • Post-CT SLN with ≤2 macrometastasis/micrometastasis or ITCs
• • Post-CT axillary response by ultrasound or MRI
• • Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment.
• Exclusion Criteria:
• • cN2
• • ypN0
• • History of breast surgery for ipsilateral cancer in the last 10 years
• • History of other cancer in the last 5 years, except squamous carcinoma of the skin.